Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Pain. 2021 Apr 1;162(4):1250–1261. doi: 10.1097/j.pain.0000000000002112

Figure 3.

Figure 3.

Effect of ST-2530 on acute pain assays. (A) Withdrawal latency (in seconds) to an aversive thermal stimulus on the hind paw (Hargreaves assay, n=12) before and after SC administration of ST-2530. Dunnett’s multiple comparison test, comparing post-dose timepoint to baseline value for each dose group: * - p<0.05, ** - p<0.01, *** - p<0.001. (B) Withdrawal latency in the Hargreaves assay (n=11-12) before and after PO dosing of PF-05089771. Dunnett’s: *** - p<0.001. (C) The Hargreaves assay 30 minutes after SC administration of ST-2530 (3 mg/kg) or vehicle (SC) and IP naloxone (2 mg/kg) or saline (IP) (n=7 per group). Bonferroni’s multiple comparison test: ** - p<0.01; *** - p<0.001. (D) Latency (in seconds) to flick tail out of 52°C water (n=8 per group). Dunnett’s, comparing post-dose timepoint to baseline value for each dose group: * - p<0.05, ** - p<0.01, ***- p<0.001. (E) Latency to bring nose within 0.5 cm of a bulldog clamp placed on the proximal end of the tail. Dunnett’s: *** - p<0.001. (F,G) Time (in seconds) spent licking hind paw following formalin injection, shown in 5 minute bins (F) or in the early (0–5 min) and late (10–45min) phases (G) (n=8 per group). Dunnett’s comparing dose groups to vehicle: * - p<0.05.